Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 377


The long non-coding RNA LINC00941 and SPRR5 are novel regulators of human epidermal homeostasis.

Ziegler C, Graf J, Faderl S, Schedlbauer J, Strieder N, Förstl B, Spang R, Bruckmann A, Merkl R, Hombach S, Kretz M.

EMBO Rep. 2019 Feb;20(2). pii: e46612. doi: 10.15252/embr.201846612. Epub 2019 Jan 8.


A phase 1 trial of vadastuximab talirine combined with hypomethylating agents in patients with CD33-positive AML.

Fathi AT, Erba HP, Lancet JE, Stein EM, Ravandi F, Faderl S, Walter RB, Advani AS, DeAngelo DJ, Kovacsovics TJ, Jillella A, Bixby D, Levy MY, O'Meara MM, Ho PA, Voellinger J, Stein AS.

Blood. 2018 Sep 13;132(11):1125-1133. doi: 10.1182/blood-2018-03-841171. Epub 2018 Jul 25.


A phase 1 trial of vadastuximab talirine as monotherapy in patients with CD33-positive acute myeloid leukemia.

Stein EM, Walter RB, Erba HP, Fathi AT, Advani AS, Lancet JE, Ravandi F, Kovacsovics T, DeAngelo DJ, Bixby D, Faderl S, Jillella AP, Ho PA, O'Meara MM, Zhao B, Biddle-Snead C, Stein AS.

Blood. 2018 Jan 25;131(4):387-396. doi: 10.1182/blood-2017-06-789800. Epub 2017 Dec 1.


Hyper-CVAD plus nelarabine in newly diagnosed adult T-cell acute lymphoblastic leukemia and T-lymphoblastic lymphoma.

Abaza Y, M Kantarjian H, Faderl S, Jabbour E, Jain N, Thomas D, Kadia T, Borthakur G, D Khoury J, Burger J, Wierda W, O'Brien S, Konopleva M, Ferrajoli A, Kebriaei P, Dabaja B, Kornblau S, Alvarado Y, Daver N, Pemmaraju N, Bose P, Thompson P, Al Azzawi H, Kelly M, Garris R, Jain P, Garcia-Manero G, Cortes J, Ravandi F.

Am J Hematol. 2018 Jan;93(1):91-99. doi: 10.1002/ajh.24947. Epub 2017 Nov 3.


Safety, efficacy, and clinical utility of asparaginase in the treatment of adult patients with acute lymphoblastic leukemia.

Koprivnikar J, McCloskey J, Faderl S.

Onco Targets Ther. 2017 Mar 6;10:1413-1422. doi: 10.2147/OTT.S106810. eCollection 2017. Review.


The role of combined fludarabine, cyclophosphamide and rituximab chemoimmunotherapy in chronic lymphocytic leukemia: current evidence and controversies.

Skarbnik AP, Faderl S.

Ther Adv Hematol. 2017 Mar;8(3):99-105. doi: 10.1177/2040620716681749. Epub 2016 Dec 1. Review.


Long-term outcome of acute promyelocytic leukemia treated with all-trans-retinoic acid, arsenic trioxide, and gemtuzumab.

Abaza Y, Kantarjian H, Garcia-Manero G, Estey E, Borthakur G, Jabbour E, Faderl S, O'Brien S, Wierda W, Pierce S, Brandt M, McCue D, Luthra R, Patel K, Kornblau S, Kadia T, Daver N, DiNardo C, Jain N, Verstovsek S, Ferrajoli A, Andreeff M, Konopleva M, Estrov Z, Foudray M, McCue D, Cortes J, Ravandi F.

Blood. 2017 Mar 9;129(10):1275-1283. doi: 10.1182/blood-2016-09-736686. Epub 2016 Dec 21.


Phase 2 study of low-dose clofarabine plus cytarabine for patients with higher-risk myelodysplastic syndrome who have relapsed or are refractory to hypomethylating agents.

Jabbour E, Faderl S, Sasaki K, Kadia T, Daver N, Pemmaraju N, Patel K, Khoury JD, Bueso-Ramos C, Bohannan Z, Ravandi F, Borthakur G, Verstovsek S, Miller D, Maduike R, Hosing C, Kantarjian HM, Garcia-Manero G.

Cancer. 2017 Feb 15;123(4):629-637. doi: 10.1002/cncr.30383. Epub 2016 Oct 14.


Long-term durable remission by cladribine followed by rituximab in patients with hairy cell leukaemia: update of a phase II trial.

Chihara D, Kantarjian H, O'Brien S, Jorgensen J, Pierce S, Faderl S, Ferrajoli A, Poku R, Jain P, Thompson P, Brandt M, Luthra R, Burger J, Keating M, Ravandi F.

Br J Haematol. 2016 Sep;174(5):760-6. doi: 10.1111/bjh.14129. Epub 2016 Jun 15.


Phase I study of evofosfamide, an investigational hypoxia-activated prodrug, in patients with advanced leukemia.

Badar T, Handisides DR, Benito JM, Richie MA, Borthakur G, Jabbour E, Harutyunyan K, Konoplev S, Faderl S, Kroll S, Andreeff M, Pearce T, Kantarjian HM, Cortes JE, Thomas DA, Konopleva M.

Am J Hematol. 2016 Aug;91(8):800-5. doi: 10.1002/ajh.24415. Epub 2016 Jun 25.


At High Levels, Constitutively Activated STAT3 Induces Apoptosis of Chronic Lymphocytic Leukemia Cells.

Rozovski U, Harris DM, Li P, Liu Z, Wu JY, Grgurevic S, Faderl S, Ferrajoli A, Wierda WG, Martinez M, Verstovsek S, Keating MJ, Estrov Z.

J Immunol. 2016 May 15;196(10):4400-9. doi: 10.4049/jimmunol.1402108. Epub 2016 Apr 13.


Prognostic impact of persistent cytogenetic abnormalities at complete remission in adult patients with acute lymphoblastic leukemia.

Short NJ, Kantarjian HM, Jabbour EJ, O'Brien SM, Faderl S, Burger JA, Garris R, Qiao W, Huang X, Jain N, Konopleva M, Kadia TM, Daver N, Borthakur G, Cortes JE, Ravandi F.

Am J Hematol. 2016 Jun;91(4):385-9. doi: 10.1002/ajh.24296. Epub 2016 Feb 9.


Ofatumumab and Lenalidomide for Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia: Correlation between Responses and Immune Characteristics.

Vitale C, Falchi L, Ten Hacken E, Gao H, Shaim H, Van Roosbroeck K, Calin G, O'Brien S, Faderl S, Wang X, Wierda WG, Rezvani K, Reuben JM, Burger JA, Keating MJ, Ferrajoli A.

Clin Cancer Res. 2016 May 15;22(10):2359-67. doi: 10.1158/1078-0432.CCR-15-2476. Epub 2016 Jan 5.


Combination of hyper-CVAD with ponatinib as first-line therapy for patients with Philadelphia chromosome-positive acute lymphoblastic leukaemia: a single-centre, phase 2 study.

Jabbour E, Kantarjian H, Ravandi F, Thomas D, Huang X, Faderl S, Pemmaraju N, Daver N, Garcia-Manero G, Sasaki K, Cortes J, Garris R, Yin CC, Khoury JD, Jorgensen J, Estrov Z, Bohannan Z, Konopleva M, Kadia T, Jain N, DiNardo C, Wierda W, Jeanis V, O'Brien S.

Lancet Oncol. 2015 Nov;16(15):1547-1555. doi: 10.1016/S1470-2045(15)00207-7. Epub 2015 Sep 30.


Long-term follow-up of a phase 2 study of chemotherapy plus dasatinib for the initial treatment of patients with Philadelphia chromosome-positive acute lymphoblastic leukemia.

Ravandi F, O'Brien SM, Cortes JE, Thomas DM, Garris R, Faderl S, Burger JA, Rytting ME, Ferrajoli A, Wierda WG, Verstovsek S, Champlin R, Kebriaei P, McCue DA, Huang X, Jabbour E, Garcia-Manero G, Estrov Z, Kantarjian HM.

Cancer. 2015 Dec 1;121(23):4158-64. doi: 10.1002/cncr.29646. Epub 2015 Aug 26.


Outcomes for patients with chronic lymphocytic leukemia and acute leukemia or myelodysplastic syndrome.

Tambaro FP, Garcia-Manero G, O'Brien SM, Faderl SH, Ferrajoli A, Burger JA, Pierce S, Wang X, Do KA, Kantarjian HM, Keating MJ, Wierda WG.

Leukemia. 2016 Feb;30(2):325-30. doi: 10.1038/leu.2015.227. Epub 2015 Aug 20.


Fludarabine, cyclophosphamide, and multiple-dose rituximab as frontline therapy for chronic lymphocytic leukemia.

Short NJ, Keating MJ, Wierda WG, Faderl S, Ferrajoli A, Estrov Z, Smith SC, O'Brien SM.

Cancer. 2015 Nov 1;121(21):3869-76. doi: 10.1002/cncr.29605. Epub 2015 Jul 28.


Outcomes of Patients With Chronic Lymphocytic Leukemia and Richter's Transformation After Transplantation Failure.

Rozovski U, Benjamini O, Jain P, Thompson PA, Wierda WG, O'Brien S, Burger JA, Ferrajoli A, Faderl S, Shpall E, Hosing C, Khouri IF, Champlin R, Keating MJ, Estrov Z.

J Clin Oncol. 2015 May 10;33(14):1557-63. doi: 10.1200/JCO.2014.58.6750. Epub 2015 Apr 6.


Final results of a phase 2 trial of clofarabine and low-dose cytarabine alternating with decitabine in older patients with newly diagnosed acute myeloid leukemia.

Kadia TM, Faderl S, Ravandi F, Jabbour E, Garcia-Manero G, Borthakur G, Ferrajoli A, Konopleva M, Burger J, Huang X, Wang X, Pierce S, Brandt M, Feliu J, Cortes J, Kantarjian H.

Cancer. 2015 Jul 15;121(14):2375-82. doi: 10.1002/cncr.29367. Epub 2015 Mar 25.


Advances in the treatment of relapsed/refractory acute lymphoblastic leukemia: a case study compendium.

Roboz GJ, Jabbour EJ, Faderl S, Douer D.

Clin Adv Hematol Oncol. 2014 Dec;12(12 Suppl 20):8-18, 1.


Barriers to physician adherence to evidence-based monitoring guidelines in chronic myelogenous leukemia.

Goldberg SL, Akard LP, Dugan MJ, Faderl S, Pecora AL.

J Oncol Pract. 2015 May;11(3):e398-404. doi: 10.1200/JOP.2014.001099. Epub 2015 Mar 10.


Phase I/II study of the hypoxia-activated prodrug PR104 in refractory/relapsed acute myeloid leukemia and acute lymphoblastic leukemia.

Konopleva M, Thall PF, Yi CA, Borthakur G, Coveler A, Bueso-Ramos C, Benito J, Konoplev S, Gu Y, Ravandi F, Jabbour E, Faderl S, Thomas D, Cortes J, Kadia T, Kornblau S, Daver N, Pemmaraju N, Nguyen HQ, Feliu J, Lu H, Wei C, Wilson WR, Melink TJ, Gutheil JC, Andreeff M, Estey EH, Kantarjian H.

Haematologica. 2015 Jul;100(7):927-34. doi: 10.3324/haematol.2014.118455. Epub 2015 Feb 14.


A retrospective study of venous thromboembolism in acute leukemia patients treated at the University of Texas MD Anderson Cancer Center.

Vu K, Luong NV, Hubbard J, Zalpour A, Faderl S, Thomas DA, Yang D, Kantarjian H, Kroll MH.

Cancer Med. 2015 Jan;4(1):27-35. doi: 10.1002/cam4.332. Epub 2014 Dec 8.


Incidence of and risk factors for involvement of the central nervous system in acute myeloid leukemia.

Rozovski U, Ohanian M, Ravandi F, Garcia-Manero G, Faderl S, Pierce S, Cortes J, Estrov Z.

Leuk Lymphoma. 2015 May;56(5):1392-7. doi: 10.3109/10428194.2014.953148. Epub 2014 Nov 3.


Gemtuzumab ozogamicin with fludarabine, cytarabine, and granulocyte colony stimulating factor (FLAG-GO) as front-line regimen in patients with core binding factor acute myelogenous leukemia.

Borthakur G, Cortes JE, Estey EE, Jabbour E, Faderl S, O'Brien S, Garcia-Manero G, Kadia TM, Wang X, Patel K, Luthra R, Koller C, Brandt M, Ravandi F, Kantarjian H.

Am J Hematol. 2014 Oct;89(10):964-8. doi: 10.1002/ajh.23795. Epub 2014 Jul 21.


A prognostic model of therapy-related myelodysplastic syndrome for predicting survival and transformation to acute myeloid leukemia.

Quintás-Cardama A, Daver N, Kim H, Dinardo C, Jabbour E, Kadia T, Borthakur G, Pierce S, Shan J, Cardenas-Turanzas M, Cortes J, Ravandi F, Wierda W, Estrov Z, Faderl S, Wei Y, Kantarjian H, Garcia-Manero G.

Clin Lymphoma Myeloma Leuk. 2014 Oct;14(5):401-10. doi: 10.1016/j.clml.2014.03.001. Epub 2014 May 6.


Outcomes of first-line treatment for chronic lymphocytic leukemia with 17p deletion.

Strati P, Keating MJ, O'Brien SM, Ferrajoli A, Burger J, Faderl S, Tambaro FP, Jain N, Wierda WG.

Haematologica. 2014 Aug;99(8):1350-5. doi: 10.3324/haematol.2014.104661. Epub 2014 May 23.


STAT3-activated GM-CSFRα translocates to the nucleus and protects CLL cells from apoptosis.

Li P, Harris D, Liu Z, Rozovski U, Ferrajoli A, Wang Y, Bueso-Ramos C, Hazan-Halevy I, Grgurevic S, Wierda W, Burger J, O'Brien S, Faderl S, Keating M, Estrov Z.

Mol Cancer Res. 2014 Sep;12(9):1267-82. doi: 10.1158/1541-7786.MCR-13-0652-T. Epub 2014 May 16.


Phase I trial of SAR103168, a novel multi-kinase inhibitor, in patients with refractory/relapsed acute leukemia or high-risk myelodysplastic syndrome.

Roboz GJ, Khoury HJ, Jabbour E, Session W, Ritchie EK, Miao H, Faderl S, Zheng W, Feldman EJ, Arellano M, Morrison JG, Ravandi F.

Leuk Lymphoma. 2015 Feb;56(2):395-400. doi: 10.3109/10428194.2014.918970.


Phase II trial of hyper CVAD and dasatinib in patients with relapsed Philadelphia chromosome positive acute lymphoblastic leukemia or blast phase chronic myeloid leukemia.

Benjamini O, Dumlao TL, Kantarjian H, O'Brien S, Garcia-Manero G, Faderl S, Jorgensen J, Luthra R, Garris R, Thomas D, Kebriaei P, Champlin R, Jabbour E, Burger J, Cortes J, Ravandi F.

Am J Hematol. 2014 Mar;89(3):282-7.


Eradication of bone marrow minimal residual disease may prompt early treatment discontinuation in CLL.

Strati P, Keating MJ, O'Brien SM, Burger J, Ferrajoli A, Jain N, Tambaro FP, Estrov Z, Jorgensen J, Challagundla P, Faderl SH, Wierda WG.

Blood. 2014 Jun 12;123(24):3727-32. doi: 10.1182/blood-2013-11-538116. Epub 2014 Apr 4.


Outcomes of patients with myelodysplatic syndrome and chronic myelomonocytic leukemia post clofarabine failure.

Ghanem H, Garcia-Manero G, Faderl S, Ravandi F, Cortes J, Katragadda L, O'Brien S, Daver N, Pierce S, Kadia T, Kantarjian H, Jabbour E.

Ther Adv Hematol. 2014 Apr;5(2):29-34. doi: 10.1177/2040620713519742.


Preclinical and early clinical evaluation of the oral AKT inhibitor, MK-2206, for the treatment of acute myelogenous leukemia.

Konopleva MY, Walter RB, Faderl SH, Jabbour EJ, Zeng Z, Borthakur G, Huang X, Kadia TM, Ruvolo PP, Feliu JB, Lu H, Debose L, Burger JA, Andreeff M, Liu W, Baggerly KA, Kornblau SM, Doyle LA, Estey EH, Kantarjian HM.

Clin Cancer Res. 2014 Apr 15;20(8):2226-35. doi: 10.1158/1078-0432.CCR-13-1978. Epub 2014 Feb 28.


Final report of phase II study of sorafenib, cytarabine and idarubicin for initial therapy in younger patients with acute myeloid leukemia.

Ravandi F, Arana Yi C, Cortes JE, Levis M, Faderl S, Garcia-Manero G, Jabbour E, Konopleva M, O'Brien S, Estrov Z, Borthakur G, Thomas D, Pierce S, Brandt M, Pratz K, Luthra R, Andreeff M, Kantarjian H.

Leukemia. 2014 Jul;28(7):1543-5. doi: 10.1038/leu.2014.54. Epub 2014 Feb 3. No abstract available.


Acute myeloid leukemia after myelodysplastic syndrome and failure of therapy with hypomethylating agents: an emerging entity with a poor prognosis.

Jabbour E, Ghanem H, Huang X, Ravandi F, Garcia-Manero G, O'Brien S, Faderl S, Pierce S, Choi S, Verstovsek S, Brandt M, Cortes J, Kantarjian H.

Clin Lymphoma Myeloma Leuk. 2014 Apr;14(2):93-7. doi: 10.1016/j.clml.2013.10.013. Epub 2013 Nov 15.


Phase I and extension study of clofarabine plus cyclophosphamide in patients with relapsed/refractory acute lymphoblastic leukemia.

Faderl S, Balakrishnan K, Thomas DA, Ravandi F, Borthakur G, Burger J, Ferrajoli A, Cortes J, O'Brien S, Kadia T, Feliu J, Plunkett W, Gandhi V, Kantarjian HM.

Clin Lymphoma Myeloma Leuk. 2014 Jun;14(3):231-8. doi: 10.1016/j.clml.2013.12.001. Epub 2013 Dec 17.


The combination of hyper-CVAD plus nelarabine as frontline therapy in adult T-cell acute lymphoblastic leukemia and T-lymphoblastic lymphoma: MD Anderson Cancer Center experience.

Jain P, Kantarjian H, Ravandi F, Thomas D, O'Brien S, Kadia T, Burger J, Borthakur G, Daver N, Jabbour E, Konopleva M, Cortes J, Pemmaraju N, Kelly MA, Cardenas-Turanzas M, Garris R, Faderl S.

Leukemia. 2014 Apr;28(4):973-5. doi: 10.1038/leu.2013.312. Epub 2013 Oct 25. No abstract available.


HCVAD plus imatinib or dasatinib in lymphoid blastic phase chronic myeloid leukemia.

Strati P, Kantarjian H, Thomas D, O'Brien S, Konoplev S, Jorgensen JL, Luthra R, Abruzzo L, Jabbour E, Quintas-Cardama A, Borthakur G, Faderl S, Ravandi F, Cortes J.

Cancer. 2014 Feb 1;120(3):373-80. doi: 10.1002/cncr.28433. Epub 2013 Oct 22.


Lack of association of IDH1, IDH2 and DNMT3A mutations with outcome in older patients with acute myeloid leukemia treated with hypomethylating agents.

DiNardo CD, Patel KP, Garcia-Manero G, Luthra R, Pierce S, Borthakur G, Jabbour E, Kadia T, Pemmaraju N, Konopleva M, Faderl S, Cortes J, Kantarjian HM, Ravandi F.

Leuk Lymphoma. 2014 Aug;55(8):1925-9. doi: 10.3109/10428194.2013.855309. Epub 2014 Feb 4. No abstract available.


The Addition of All-Trans Retinoic Acid to Chemotherapy May Not Improve the Outcome of Patient with NPM1 Mutated Acute Myeloid Leukemia.

Nazha A, Bueso-Ramos C, Estey E, Faderl S, O'Brien S, Fernandez MH, Nguyen M, Koller C, Freireich E, Beran M, Pierce S, Keating M, Cortes J, Kantarjian H, Ravandi F.

Front Oncol. 2013 Sep 6;3:218. doi: 10.3389/fonc.2013.00218. eCollection 2013.


Mutated NPM1 in patients with acute myeloid leukemia in remission and relapse.

Jain P, Kantarjian H, Patel K, Faderl S, Garcia-Manero G, Benjamini O, Borthakur G, Pemmaraju N, Kadia T, Daver N, Nazha A, Luthra R, Pierce S, Cortes J, Ravandi F.

Leuk Lymphoma. 2014 Jun;55(6):1337-44. doi: 10.3109/10428194.2013.840776. Epub 2013 Oct 9.


Phase I clinical, pharmacokinetic, and pharmacodynamic study of the Akt-inhibitor triciribine phosphate monohydrate in patients with advanced hematologic malignancies.

Sampath D, Malik A, Plunkett W, Nowak B, Williams B, Burton M, Verstovsek S, Faderl S, Garcia-Manero G, List AF, Sebti S, Kantarjian HM, Ravandi F, Lancet JE.

Leuk Res. 2013 Nov;37(11):1461-7. doi: 10.1016/j.leukres.2013.07.034. Epub 2013 Aug 6.


Biological and clinical features of trisomy 21 in adult patients with acute myeloid leukemia.

Strati P, Daver N, Ravandi F, Pemmaraju N, Pierce S, Garcia-Manero G, Nazha A, Kadia T, Jabbour E, Borthakur G, Faderl S, Quintas-Cardama A, Kantarjian H, Cortes J.

Clin Lymphoma Myeloma Leuk. 2013 Sep;13 Suppl 2:S276-81. doi: 10.1016/j.clml.2013.05.020. Epub 2013 Aug 19.


Patient-driven discontinuation of tyrosine kinase inhibitors: single institution experience.

Benjamini O, Kantarjian H, Rios MB, Jabbour E, O'Brien S, Jain P, Cardenas-Turanzas M, Faderl S, Garcia-Manero G, Ravandi F, Borthakur G, Quintas-Cardama A, Cortes J.

Leuk Lymphoma. 2014 Dec;55(12):2879-86. doi: 10.3109/10428194.2013.831092. Epub 2013 Sep 10.


Clofarabine, idarubicin, and cytarabine (CIA) as frontline therapy for patients ≤60 years with newly diagnosed acute myeloid leukemia.

Nazha A, Kantarjian H, Ravandi F, Huang X, Choi S, Garcia-Manero G, Jabbour E, Borthakur G, Kadia T, Konopleva M, Cortes J, Ferrajoli A, Kornblau S, Daver N, Pemmaraju N, Andreeff M, Estrov Z, Du M, Brandt M, Faderl S.

Am J Hematol. 2013 Nov;88(11):961-6. doi: 10.1002/ajh.23544. Epub 2013 Sep 9.


Detection of MRD may predict the outcome of patients with Philadelphia chromosome-positive ALL treated with tyrosine kinase inhibitors plus chemotherapy.

Ravandi F, Jorgensen JL, Thomas DA, O'Brien S, Garris R, Faderl S, Huang X, Wen S, Burger JA, Ferrajoli A, Kebriaei P, Champlin RE, Estrov Z, Challagundla P, Wang SA, Luthra R, Cortes JE, Kantarjian HM.

Blood. 2013 Aug 15;122(7):1214-21. doi: 10.1182/blood-2012-11-466482. Epub 2013 Jul 8.


A model for prediction of FLT3-ITD and NPM1 (without FLT3-ITD) positivity in patients with newly diagnosed acute myeloid leukaemia.

Ostronoff F, Othus M, Kantarjian HM, Meshinchi S, Ravandi F, Hendrie PC, Faderl S, Becker PS, Cortes JE, Pagel JM, Petersdorf SH, Godwin JE, Willman CL, Pierce SA, List AF, Sandhu RK, Walter RB, Stirewalt DL, Appelbaum FR, Estey EH.

Br J Haematol. 2013 Oct;163(1):130-2. doi: 10.1111/bjh.12450. Epub 2013 Jul 6. No abstract available.


Fludarabine, cyclophosphamide and rituximab plus granulocyte macrophage colony-stimulating factor as frontline treatment for patients with chronic lymphocytic leukemia.

Strati P, Ferrajoli A, Lerner S, O'Brien S, Wierda W, Keating MJ, Faderl S.

Leuk Lymphoma. 2014 Apr;55(4):828-33. doi: 10.3109/10428194.2013.819574. Epub 2013 Jul 29.


Dynamic acquisition of FLT3 or RAS alterations drive a subset of patients with lower risk MDS to secondary AML.

Takahashi K, Jabbour E, Wang X, Luthra R, Bueso-Ramos C, Patel K, Pierce S, Yang H, Wei Y, Daver N, Faderl S, Ravandi F, Estrov Z, Cortes J, Kantarjian H, Garcia-Manero G.

Leukemia. 2013 Oct;27(10):2081-3. doi: 10.1038/leu.2013.165. Epub 2013 Jun 7. No abstract available.


Expectations of serious adverse events at the end of life of patients with acute myeloid leukemia who receive salvage therapy.

Cardenas-Turanzas M, Ravandi-Kashani F, Cortes JE, Jabbour E, Faderl S, Pierce SA, Kantarjian H.

Clin Lymphoma Myeloma Leuk. 2013 Oct;13(5):579-83. doi: 10.1016/j.clml.2013.03.021. Epub 2013 Jun 10.

Supplemental Content

Loading ...
Support Center